Related Experiment Video

Updated: May 1, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K

Clinical Development of Novel-Novel Multi-Company Combination Therapies in Oncology

Patrick Y Muller1, Johannes Eisinger2, Pakeeza Sayyed3

  • 1Bristol-Myers Squibb, Hematology Clinical Development, Boudry, Switzerland. patrick.mueller@bms.com.

Current Oncology Reports
|April 30, 2026
PubMed
Abstract

Insights

Developing novel combination cancer therapies early is crucial. This review addresses challenges and solutions for multi-company investigational drug combinations in oncology.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Drug Development

Background:

  • Novel anti-cancer therapies increasingly combine immuno-oncology and targeted drugs.
  • The trend is shifting towards developing novel combination therapies with multiple investigational agents early in the process.

Purpose of the Study:

  • To discuss the challenges and propose solutions for developing novel combination therapies involving multiple investigational agents, particularly when multiple companies are involved.
  • To accelerate the evolution of the standard of care for cancers with high unmet needs.

Main Methods:

  • Critical discussion of challenges based on a consortium of major oncology drug developers.
  • Exploration of strategies for early and late clinical development of combination therapies.

Main Results:

  • Identified key challenges in developing novel multi-company combination therapies.
  • Suggested potential solutions and strategies for trial design, safety, and regulatory aspects.

Conclusions:

  • Early development of novel combination therapies is essential for advancing cancer care.
  • Addressing challenges in multi-company collaborations is key to successfully bringing these therapies to patients with solid and hematological tumors.
Keywords:
CancerClinical developmentCombination therapiesDevelopment strategyHematologyNovel-novelOncologyTrial design

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K